Details

Autor(en) / Beteiligte

• Deschildre, Antoine
• Marguet, Christophe
• Langlois, Carole
• Pin, Isabelle
• Rittié, Jean-Luc
• Derelle, Jocelyne
• Abou Taam, Rola
• Fayon, Michael
• Brouard, Jacques
• Dubus, Jean Christophe
• Siret, Daniel
• Weiss, Laurence
• Pouessel, Guillaume
• Beghin, Laurent
• Just, Jocelyne

Titel

Real-life long-term omalizumab therapy in children with severe allergic asthma

Ist Teil von

• The European respiratory journal, 2015-09, Vol.46 (3), p.856-859

Ort / Verlag

England

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• We previously reported the French real-life experience of 1year of add-on treatment with omalizumab in 101 severe allergic asthmatic children (6-18years), 92 of whom were still receiving the treatment at the end of the first year [1]. The study provided complementary data to the previous randomised trials [2-6]. We showed a marked drop of 72% in the mean rate of severe exacerbations (from 4.4 per patient during the preceding year to 1.25 during the year of treatment) and of 88.5% for hospitalisations (44% of the patients during the preceding year to 6.7% during the year of treatment); a large improvement in asthma control (from 0% at initiation to 67% of well-controlled patients after 1year); a decrease of 30% of the mean inhaled corticosteroid (ICS) dose (from 703 at initiation to 488 mu g fluticasone equivalent per day after 1year); and a forced expiratory volume in 1s (FEV1) increase, from a mean of 88% to 92.1% of the predicted value. Treatment was discontinued in six patients due to serious adverse events attributed to omalizumab by the practitioner. Here we report the outcome of this cohort after 2years of omalizumab treatment.